BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2025 Q1 P&L / Income Statement

Revenue by Product and Service by Arrangement

2025-01-01 to 2025-03-31

Swipe to see the full flow
BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2025 Q1 P&L / Income StatementIncome statement for 2025-01-01 through 2025-03-31. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETNet product sales - Collaborative ArrangementEliquisOpdivoOrenciaYervoyAlliance revenues - Collaborative ArrangementCobenfyOther revenuesTotal RevenuesGross profit (calculated)Cost of products soldOperating profit (calculated)Operating expenses (calculated)Earnings/(Loss) before income taxesNet earnings/(loss)Income tax provisionGross profit (calculated)Gross profit(calculated)$8.17 BOperating profit (calculated)Operating profit(calculated)$2.97 BEarnings/(Loss) before income taxesEarnings/(Loss)before income taxes$2.97 BTotal RevenuesTotal Revenues$11.20 BNet earnings/(loss)Net earnings/(loss)$2.46 BNet product sales - Collaborative ArrangementNet product sales -Collaborative Arrangement$3.64 BOperating expenses (calculated)Operating expenses(calculated)$5.20 BIncome tax provisionIncome taxes$509.00 MEliquisEliquis$3.57 BOpdivoOpdivo$2.27 BCost of products soldCost of products sold$3.03 BOrenciaOrencia$770.00 MYervoyYervoy$624.00 MAlliance revenues - Collaborative ArrangementAlliance revenues -Collaborative Arrangement$88.00 MCobenfyCobenfy$27.00 MOther revenuesOther revenues$227.00 M
Chart details

BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total Revenues
11,201,000,000 US dollars
Cost of products sold
3,033,000,000 US dollars
Gross profit (calculated)
8,168,000,000 US dollars
Operating expenses (calculated)
5,197,000,000 US dollars
Operating profit (calculated)
2,971,000,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Earnings/(Loss) before income taxes
2,971,000,000 US dollars
Income tax provision
509,000,000 US dollars
Net earnings/(loss)
2,462,000,000 US dollars
Other revenues
227,000,000 US dollars
Cobenfy
27,000,000 US dollars
Eliquis
3,565,000,000 US dollars
Opdivo
2,265,000,000 US dollars
Orencia
770,000,000 US dollars
Yervoy
624,000,000 US dollars
Alliance revenues - Collaborative Arrangement
88,000,000 US dollars
Net product sales - Collaborative Arrangement
3,635,000,000 US dollars
Selling, general and administrative
1,584,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Research and development
2,257,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Acquired IPRD
188,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Amortization of acquired intangible assets
830,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Other (income)/expense, net
339,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2025 Q1 Revenue by Product and Service by Arrangement Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

72.9%

Gross profit / revenue

Operating margin

26.5%

Operating profit / revenue

Cash conversion

79.4%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!